Christophe Massard
Institut Gustave Roussy
CancerPathologyOncologyProstate cancerMedicine
What is this?
Publications 539
#1F. Facchinetti (Institut Gustave Roussy)H-Index: 3
#2Ludovic LacroixH-Index: 42
Last. Stefan MichielsH-Index: 50
view all 19 authors...
INTRODUCTION: BRAF is a confirmed therapeutic target in non-small cell lung cancer (NSCLC), as the BRAF inhibitor dabrafenib, in combination with the MEK inhibitor trametinib, is approved for the treatment of NSCLC harbouring BRAF V600E mutation. Scant evidence is available concerning the mechanisms of resistance to BRAF/MEK inhibitors in BRAF(V600E) NSCLC. PATIENTS AND METHODS: Patients with BRAF(V600E) NSCLC with acquired resistance to BRAF/MEK inhibitors were included in the institutional, pr...
#1Robin L. Jones (The Royal Marsden NHS Foundation Trust)H-Index: 36
#2Teresa MacarullaH-Index: 27
Last. Patricia Roxburgh (Beatson West of Scotland Cancer Centre)H-Index: 7
view all 20 authors...
#1Patricia MartinH-Index: 4
#2Sigi Neerken (Philips)H-Index: 1
Last. Christophe MassardH-Index: 43
view all 11 authors...
#1Cyrus ChargariH-Index: 24
#2Antonin LevyH-Index: 22
Last. Eric Deutsch (Institut Gustave Roussy)H-Index: 43
view all 7 authors...
Newer technical improvements in radiation oncology have been rapidly implemented in recent decades, allowing an improved therapeutic ratio. The development of strategies using local and systemic treatments concurrently, mainly targeted therapies, has however plateaued. Targeted molecular compounds and immunotherapy are increasingly being incorporated as the new standard of care for a wide array of cancers. A better understanding of possible prior methodology issues is therefore required and shou...
#1Clément Dumont (Institut Gustave Roussy)
#1Clement DumontH-Index: 1
Last. Alberto BossiH-Index: 24
view all 12 authors...
INTRODUCTION: Neoadjuvant chemotherapy with docetaxel and estramustine (DE) significantly improved relapse-free survival in patients with high-risk localized prostate cancer treated with androgen deprivation therapy (ADT) for 3 years and a local treatment in the GETUG-12 phase III trial. We sought to explore whether the addition of DE impacts long-term treatment-related side effects. PATIENTS AND METHODS: Patients randomized within the UNICANCER GETUG-12 trial at Gustave Roussy who were alive wh...
#1Caroline Even (Institut Gustave Roussy)H-Index: 12
#2Ulrik Lassen (Rigshospitalet)H-Index: 28
Last. Christophe Massard (Institut Gustave Roussy)H-Index: 43
view all 13 authors...
Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911–17). Methods Patients with advanced or metastatic cancer, measurable diseas...
2 CitationsSource
#2Lizza E.L. Hendriks (UM: Maastricht University)H-Index: 12
Last. Benjamin BesseH-Index: 43
view all 22 authors...
Abstract Introduction In patients with oncogene-addicted NSCLC and isolated central nervous system progression (iCNS), tissue biopsy is challenging and the clinical utility of plasma liquid biopsy (ctDNA) is unknown. Methods Advanced NSCLC patients with known baseline genomic alteration (GA) (EGFR, ALK, BRAF, KRAS, HER2, ROS1, MET, PIK3CA, STK11, TP53) on tissue were divided in to 3 groups based on their disease progression pattern: iCNS, extra-CNS only (noCNS) or both (cCNS). All patients with ...
2 CitationsSource
#1Miruna GreceaH-Index: 1
#2Aurélien Marabelle (French Institute of Health and Medical Research)H-Index: 24
Last. Stéphane ChampiatH-Index: 17
view all 5 authors...
A breakthrough in oncology over the last 5 years, immunotherapy has proved its salutary effects in a wide range of solid tumors. The targeting of the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway can restore a competent antitumor T-cell response by addressing key tumor immune evasion mechanisms. This novel mechanism of action is associated with new patterns of responses that were not observed with conventional treatments such as chemotherapy or targeted therapi...
2 CitationsSource
#1M SmoragiewiczH-Index: 1
#2Alex A. Adjei (Mayo Clinic)H-Index: 63
Last. Lesley Seymour (Queen's University)H-Index: 57
view all 10 authors...
Purpose: To review key aspects of the design and conduct of early clinical trials (ECT) of immunotherapy agents. Design: The Methodology for the Development of Innovative Cancer Therapies (MDICT) Task Force 2019 included experts from academia, non-profit organisations, industry and regulatory agencies. The review focus was on methodology for ECTs testing immune-oncology therapies (IO) used in combination with other IO or chemotherapy. Results: Although early successes have been seen, the landsca...
#1Zhen Shi (Genentech)H-Index: 2
#2Christopher Sweeney (Harvard University)H-Index: 57
Last. Marie-Laurence Harle-Yge (Hoffmann-La Roche)H-Index: 2
view all 13 authors...
182Background: IPATential150 is a randomized trial comparing Ipat + Abi vs placebo + Abi in patients (pts) with 1L mCRPC (NCT03072238). We evaluated the potential associations between PTEN loss, ge...